- Home
- PODC vs CYCC Comparison
PODC vs CYCC Comparison
Compare PODC & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- CYCC
- Stock Information
- Founded
- PODC 2013
- CYCC 1992
- Country
- PODC United States
- CYCC Malaysia
- Employees
- PODC N/A
- CYCC N/A
- Industry
- PODC
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- CYCC Health Care
- Exchange
- PODC Nasdaq
- CYCC Nasdaq
- Market Cap
- PODC 44.1M
- CYCC 47.6M
- IPO Year
- PODC N/A
- CYCC N/A
- Fundamental
- Price
- PODC $1.94
- CYCC $0.25
- Analyst Decision
- PODC Strong Buy
- CYCC Strong Buy
- Analyst Count
- PODC 1
- CYCC 1
- Target Price
- PODC $5.00
- CYCC $11.00
- AVG Volume (30 Days)
- PODC 23.7K
- CYCC 7.3M
- Earning Date
- PODC 05-29-2025
- CYCC 05-20-2025
- Dividend Yield
- PODC N/A
- CYCC 59.13%
- EPS Growth
- PODC N/A
- CYCC N/A
- EPS
- PODC N/A
- CYCC N/A
- Revenue
- PODC $49,729,000.00
- CYCC $43,000.00
- Revenue This Year
- PODC $20.67
- CYCC $137.21
- Revenue Next Year
- PODC $19.09
- CYCC N/A
- P/E Ratio
- PODC N/A
- CYCC N/A
- Revenue Growth
- PODC 22.98
- CYCC N/A
- 52 Week Low
- PODC $1.10
- CYCC $0.17
- 52 Week High
- PODC $2.85
- CYCC $3.08
- Technical
- Relative Strength Index (RSI)
- PODC 54.47
- CYCC 47.06
- Support Level
- PODC $1.71
- CYCC $0.28
- Resistance Level
- PODC $1.99
- CYCC $0.37
- Average True Range (ATR)
- PODC 0.19
- CYCC 0.07
- MACD
- PODC 0.01
- CYCC 0.01
- Stochastic Oscillator
- PODC 38.75
- CYCC 20.67
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.